Clinical TrialJun 1, 2026, 08:08 AM
Immatics Reports Strong Clinical Activity for 3 PRAME Therapies
AI Summary
Immatics N.V. presented updated Phase 1/1b clinical data for three PRAME-targeting therapies (IMA203CD8, IMA401, and anzu-cel) at the 2026 ASCO Annual Meeting, demonstrating significant anti-tumor activity and manageable tolerability across various hard-to-treat solid tumors. IMA203CD8 showed a 63% ORR in gynecologic cancers and 67% ORR in synovial sarcoma. IMA401 achieved a 29% cORR in head and neck cancer and is advancing into a combination trial with IMA402 in lung cancer. Anzu-cel reported a 56% cORR in metastatic melanoma with durable responses, keeping its Phase 3 SUPRAME trial on track for BLA submission in 1H 2027.
Key Highlights
- IMA203CD8 achieved 63% objective response rate (ORR) and 50% confirmed ORR (cORR) in gynecologic cancers, including four complete responses.
- IMA203CD8 showed 67% ORR and 64% cORR in synovial sarcoma, with ongoing responses up to approximately 3 years.
- IMA401 demonstrated 29% confirmed ORR (4/14) in head and neck cancer at recommended Phase 2 dose (RP2D), with 8.8 months median duration of response (mDOR).
- The IMA401/IMA402 combination cohort is now enrolling for squamous cell non-small cell lung cancer (sqNSCLC), with first data expected in 2027.
- Anzu-cel (IMA203) achieved 56% confirmed ORR in metastatic melanoma, with 14.6 months mDOR, 6.1 months mPFS, and 16.2 months mOS.
- Anzu-cel's Phase 3 SUPRAME trial remains on track for Biologics License Application (BLA) submission in 1H 2027.
- All three PRAME-targeting therapies demonstrated manageable and consistent tolerability profiles across patient populations.
- PRAME is expressed in more than 50 cancers, supporting the broad applicability of Immatics' PRAME franchise.
Price Impact
More from IMTX